HIV/AIDS Statistics for Brazil
Total population in thousands (2007): 191,791*
Number of people living with HIV (2007): 730,000*
Adults aged 15 to 49 prevalence rate (2007): 0.6*
Adults aged 15 and up living with HIV (2007): 710,000*
Women aged 15 and up living with HIV (2007): 240,000*
Deaths due to AIDS (2007): 15,000*
Estimated antiretroviral therapy coverage (Dec 2007): 80%†
Ongoing biomedical HIV prevention research trials in Brazil
Vaccines
Trial: HVTN 084
Phase: I
Start Date: February 2011
Sponsor, funder, developer: DAIDS, HVTN, VRC
Vaccine(s): rAd5:(VRC-HIVADV014-00-VP); rAd5:(VRC-HIVADV054-00-VP)
Inserts: ADV014:clade B gag-pol; clades A, B, C env; ADV054: clade B gag-pol
Clade: A, B, C
Trial: HVTN 204
Phase: II
Start Date: August 2006
Sponsor, funder, developer: NIAID, HVTN
Total participants: 480
Vaccine(s): DNA vaccine: VRC-HIVDNA016-00-VP, followed by adenoviral vector vaccine, VRC-HIVADV014-00-VP
Clade: A, B, C
Back to Top ↑
Pre-Exposure Prophylaxis
Trial: Pre-Exposure Prophylaxis Initiative [iPrEx]
Phase: III
Product Being Tested: Daily oral TDF/FTC (Truvada®)
Sponsor, funder, developer, collaborator: National Institute of Health, Bill and Melinda Gates Foundation, Fenway Community Health, San Francisco Department of Public Health
Total participants: 2,499
Countries: Brazil, Ecuador, Peru, South Africa, Thailand, US
Trial sites in US: Boston, MA
Results expected: Announced in Q4 2010. For more information visit the
Global iPrEx page or
AVAC's iPrEx page
Back to Top ↑
Partner Treatment
Trial: Evaluation of the effectiveness of two antiretroviral treatment strategies to prevent HIV transmission in HIV-serodiscordant couples [HPTN 052]
Phase: III
Product Being Tested: Highly active antiretroviral therapy for HIV prevention
Sponsor, funder, developer, collaborator: HIV Prevention Trials Network, Instituto de Pesquisa Clinica Evandro Chagas Clinical Research Site, Hospital Geral de Nova Iguaçu, Hospital Nossa Senhora da Conceicao, HSE-Hospital dos Servidores do Estado
Total participants: 1,750 couples
Countries: Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand, Zimbabwe
Trial sites in Brazil: Manguinhos, Nova Iguacu, Porto Alegre, Rio de Janeiro
Results expected: 2013
For more information: http://www.hptn.org/research_studies/hptn052.asp